| 44.54 0.5 (1.14%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 56.88 | 1-year : | 66.43 |
| Resists | First : | 48.7 | Second : | 56.88 |
| Pivot price | 42.23  |
|||
| Supports | First : | 36.67 | Second : | 29.23 |
| MAs | MA(5) : | 43.48 |
MA(20) : | 39.25 |
| MA(100) : | 36.73 |
MA(250) : | 28.35 |
|
| MACD | MACD : | 2.9  |
Signal : | 2.6 |
| %K %D | K(14,3) : | 73.9 |
D(3) : | 72.1 |
| RSI | RSI(14): 63.6 |
|||
| 52-week | High : | 48.7 | Low : | 9.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ KYMR ] has closed below upper band by 35.7%. Bollinger Bands are 103.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 45.32 - 45.5 | 45.5 - 45.68 |
| Low: | 42.85 - 43.05 | 43.05 - 43.24 |
| Close: | 44.22 - 44.53 | 44.53 - 44.83 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Fri, 26 Jul 2024
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Ameritas Investment Partners Inc. - Defense World
Thu, 25 Jul 2024
We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn - Yahoo Finance
Wed, 24 Jul 2024
ProShare Advisors LLC Acquires 1,775 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Tue, 23 Jul 2024
Swiss National Bank Increases Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Tue, 16 Jul 2024
Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating (NASDAQ:KYMR) - Seeking Alpha
Sun, 14 Jul 2024
Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 111.8 (%) |
| Shares Short | 9,380 (K) |
| Shares Short P.Month | 9,990 (K) |
| EPS | -2.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.59 |
| Profit Margin | -194.7 % |
| Operating Margin | -514.3 % |
| Return on Assets (ttm) | -14.7 % |
| Return on Equity (ttm) | -26.4 % |
| Qtrly Rev. Growth | 8.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.29 |
| EBITDA (p.s.) | -2.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -98 (M) |
| Levered Free Cash Flow | -110 (M) |
| PE Ratio | -17.75 |
| PEG Ratio | -7.3 |
| Price to Book value | 3.84 |
| Price to Sales | 34.41 |
| Price to Cash Flow | -27.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|